Brief: Mesoblast Says Regenerative Medicine Advanced Therapy Designation granted For Rexlemestrocel-L
08/02/2023 22:41
Feb 9 (Reuters) - Mesoblast MSB.AX :
* US FDA GRANTS REGENERATIVE MEDICINE ADVANCED THERAPY
(RMAT)
DESIGNATION FOR REXLEMESTROCEL-L
Source text for Eikon: ID:nASX5k8DcN
Further company coverage: MSB.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mesoblast
See all newsBrief: Mesoblast Reports QTRLY Ryoncil Net Revenues Of $30.3 Million
ASX-shares of Mesoblast rise after back-treatment drug hits patent target
Australia's Mesoblast soars on bagging licence for Mayo Clinic-developed tech
Brief: Mesoblast Acquires CAR Platform For Precision-Enhanced Cell Products
Brief: Mesoblast Says Ryoncil's Net Revenue For Quarter Increases To US$30.3M